Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Sees Significant Growth in Short Interest

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the recipient of a large increase in short interest in October. As of October 31st, there was short interest totalling 160,100 shares, an increase of 58.7% from the October 15th total of 100,900 shares. Based on an average daily trading volume, of 117,900 shares, the days-to-cover ratio is currently 1.4 days.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ENLV. EF Hutton Acquisition Co. I upgraded shares of Enlivex Therapeutics to a “strong-buy” rating in a research report on Tuesday, August 27th. HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of Enlivex Therapeutics in a research report on Friday, September 27th.

Enlivex Therapeutics Trading Down 0.9 %

Shares of ENLV stock opened at $1.07 on Friday. Enlivex Therapeutics has a 12 month low of $1.01 and a 12 month high of $4.59. The stock has a market cap of $22.91 million, a P/E ratio of -0.92 and a beta of 1.11. The company has a 50 day simple moving average of $1.45 and a two-hundred day simple moving average of $1.40.

Enlivex Therapeutics (NASDAQ:ENLV) last announced its earnings results on Friday, August 30th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.06. As a group, equities analysts forecast that Enlivex Therapeutics will post -0.7 earnings per share for the current year.

Hedge Funds Weigh In On Enlivex Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. XTX Topco Ltd bought a new position in shares of Enlivex Therapeutics during the second quarter worth $35,000. Sigma Investment Counselors Inc. bought a new position in Enlivex Therapeutics during the third quarter valued at $50,000. Finally, Armistice Capital LLC bought a new position in Enlivex Therapeutics during the second quarter valued at $2,415,000. Institutional investors own 1.02% of the company’s stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.